Cogane demonstrated positive results in preclinical in vitro and in vivo models of ALS.
There is an ongoing study of Cogane in the genetic ‘gold standard’ in vivo model of ALS, which is supported by the UK-based Motor Neurone Disease Association.
Results from the study are expected to be announced in Q4 2011.
Cogane received Orphan Drug status by the United States Food & Drug Administration (US FDA) in July 2011.